EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Molecular features of human pathological tau distinguish tauopathy-associated dementias

Mukesh Kumar, Christoph N Schlaffner, Shaojun Tang, Maaike A Beuvink, Arthur Viode, Waltraud Mair, Meenakshi Jha, Ceren Uncu, Hendrik Wesseling, Tian Wang, Derek H Oakley, Pieter Beerepoot und 19 weitere

Cell · 2026-02 · 189 (3) · 956-968.e13

DOI: 10.1016/j.cell.2025.12.036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell, 2026-02. Verfasst von Mukesh Kumar und 30 weiteren Autor:innen. Beteiligte Einrichtung: F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: tau Proteins, Tauopathies, Dementia. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In Alzheimer's disease (AD), pathological tau protein shows a progressive accumulation of post-translational modifications (PTMs), reflecting disease severity, progression, and prion-like activity. Although many neurodegenerative diseases with dementia display tau aggregates, the pathological proteoforms of tau protein from each disease type remain unknown. Here, using a quantitative mass spectrometry-based proteomics platform, FLEXITau, deep characterization of pathological tau protein isolated from the brains of 203 human subjects with AD, familial AD (fAD), chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), Pick's disease (PiD), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB)-a non-tauopathy symptomatic control-and healthy controls (CTR) is performed. Unsupervised data analyses and supervised machine learning identify distinct molecular features of pathological tau for each disease, enabling molecular disease stratification. This study identifies potential disease-specific biomarkers and therapeutic targets for tauopathies and provides critical quantitative information for pharmacokinetic modeling required for therapeutic and disease mechanism studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsTauopathiesDementiaHumansProteomicsFemaleAlzheimer DiseaseMaleBrainSupranuclear Palsy, ProgressiveAgedBiomarkersCorticobasal DegenerationLewy Body DiseaseProtein Processing, Post-TranslationalChronic Traumatic EncephalopathyPick Disease of the BrainMass SpectrometryMiddle AgedAged, 80 and overMachine Learning

Stichwörter der Autor:innen

MRMPTMsbiomarkerscleavagemachine learningmass spectrometryneurodegenerative diseasesproteomicstau proteintherapeutics

Substanzen

tau ProteinsBiomarkers

Autor:innen und Institutionen

  • F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA; Data Analytics and Computational Statistics, Hasso Plattner Institute, Digital Engineer…
  • F.M. Kirby Neurobiology Center, Department of Neurobiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA; Department of Biostatistics, Massey Comprehensive Cancer Center, Virginia Commonwealth…
  • Departments of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
  • Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • UMMG Department of Neurology, Miller School of Medicine, Medical Campus, University of Miami, Miami, FL, USA.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS
  • University of Miami
  • University of Maryland
  • Cure Alzheimer's Fund
  • European Research Council
  • Ellison Medical Foundation

Zitieren

APA

Kumar, M., Schlaffner, C. N., Tang, S., Beuvink, M. A., Viode, A., Mair, W., Jha, M., Uncu, C., Wesseling, H., Wang, T., Oakley, D. H., Beerepoot, P., Xue, J., Connors, T. R., Davis, D. A., Frosch, M. P., Murray, M. E., Spina, S. E., Grinberg, L. T., …, & Steen, J. A. (2026). Molecular features of human pathological tau distinguish tauopathy-associated dementias. Cell, 189(3), 956-968.e13. https://doi.org/10.1016/j.cell.2025.12.036

Vancouver

Kumar M, Schlaffner CN, Tang S, Beuvink MA, Viode A, Mair W, et al. Molecular features of human pathological tau distinguish tauopathy-associated dementias. Cell. 2026;189(3):956-968.e13. doi:10.1016/j.cell.2025.12.036

BibTeX
@article{Kumar2026,
  author = {Kumar, Mukesh and Schlaffner, Christoph N and Tang, Shaojun and Beuvink, Maaike A and Viode, Arthur and Mair, Waltraud and Jha, Meenakshi and Uncu, Ceren and Wesseling, Hendrik and Wang, Tian and Oakley, Derek H and Beerepoot, Pieter and Xue, Jie and Connors, Theresa R and Davis, David A and Frosch, Matthew P and Murray, Melissa E and Spina, Salvatore E and Grinberg, Lea T and Seeley, William W and Miller, Bruce L and Boxer, Adam L and Geschwind, Daniel H and Kosik, Kenneth S and Dickson, Dennis W and Renard, Bernhard Y and DeTure, Michael and McKee, Ann C and Hyman, Bradley T and Steen, Hanno and Steen, Judith A},
  title = {Molecular features of human pathological tau distinguish tauopathy-associated dementias},
  journal = {Cell},
  year = {2026},
  volume = {189},
  number = {3},
  pages = {956--968.e13},
  doi = {10.1016/j.cell.2025.12.036}
}
Kostenlos starten →